LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was...
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.